Rockville, MD, November 12, 2010 --(PR.com
)-- MarketResearch.com has announced the addition of GBI Research’s new report “Oral Drug Delivery Market - Controlled and Sustained Release to be Major Revenue Generators” to their collection of Drug Delivery market reports. For more information, visit http://www.marketresearch.com/product/display.asp?ProductID=2847728
Over the last few years, the pharmaceutical industry has seen patent expiries for major blockbuster drugs which have resulted in losses worth billions. More blockbuster drugs are about to lose patent in the coming years. In such a situation, pharmaceutical companies are increasingly adopting various drug delivery systems to enhance their product efficacy, patient compliance and extend patent lives through innovative repositioning and reformulations of existing drugs. This has resulted in significant growth in the drug delivery market over the last few years. According to GBI Research, the overall drug delivery market is forecasted to grow to $199 billion in 2016 from $101 billion in 2009, at a CAGR of 10.3%.
Central Nervous System (CNS) agents, hormone-related agents and gastrointestinal agents are among the key therapeutic areas witnessing the use of innovative drug delivery methods, and this trend is expected to grow in the coming years.
The oral drug delivery market remains the largest segment of the overall drug delivery market, with more than 52% of the market share. It is presently valued at $49 billion and is expected to reach $92 billion by 2016, at a CAGR of 11.3%. The growth in the oral drug delivery market shall be driven primarily by newer technologies enabling controlled release formulations of oral drugs and oral formulations of injectible only drugs.
Other innovative technologies like nanotechnology-enabled oral drugs and oral forms of prodrugs have also seen significant research and development over the past few years, both in academic circles as well as in the industry as a whole.
Innovative oral formulations like orally disintegrating tablets, fast dissolving tablets and mini-tablets have been introduced into the market, which ensure better patient compliance, reduce dosage frequencies and enable customizable drug loading.
For more information, visit http://www.marketresearch.com/product/display.asp?ProductID=2847728